Recent Quotes
View Full List
My Watchlist
Cloudmd Software & Services Inc
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
132.85
-4.93 (-3.57%)
Delayed Quote
Updated: 1:48 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma
↗
Today 8:13 EST
Merck & Co., Inc. (NYSE:MRK) is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the...
Via
MarketBeat
Topics
Artificial Intelligence
Merck and Isomorphic Labs Enter Strategic Research Collaboration
Today 6:45 EST
From
Merck & Co., Inc.
Via
Business Wire
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
↗
Today 1:20 EST
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
Via
The Motley Fool
Topics
Artificial Intelligence
Dow Jones Top Movers: Decliners Lead Nov. 18, 2026 Session
↗
November 18, 2026
Via
Chartmill
Topics
Stocks
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines
↗
November 03, 2026
Via
Chartmill
Topics
Stocks
Dow Jones Biggest Decliners in Today's US Session
↗
November 03, 2026
Via
Chartmill
Topics
Stocks
Dow Jones Gainers and Losers: Top Movers in Nov. 18, 2026 US Session
↗
November 18, 2026
Via
Chartmill
Topics
Stocks
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
November 18, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
November 17, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2027 Dividend
November 17, 2026
From
Merck & Co., Inc.
Via
Business Wire
Is Merck's Stock Still a Good Buy at $150?
↗
November 16, 2026
The healthcare stock has surged nearly 40% this year.
Via
The Motley Fool
Topics
Intellectual Property
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
November 13, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
November 13, 2026
From
Merck & Co., Inc.
Via
Business Wire
3 Pharmaceutical Stocks That Offer Safety and Growth
↗
November 12, 2026
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Merck to Participate in the Jefferies Global Healthcare Conference in London
November 12, 2026
From
Merck & Co., Inc.
Via
Business Wire
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
↗
November 11, 2026
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via
MarketBeat
Topics
Artificial Intelligence
Bankruptcy
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
November 09, 2026
From
Merck & Co., Inc.
Via
Business Wire
Moderna Just Gave Investors Yet Another Thing to Cheer About
↗
November 06, 2026
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.
Via
The Motley Fool
2 Growth Stocks to Buy in November Without Any Hesitation
↗
November 05, 2026
They have both outperformed the broader equity market over the long run.
Via
The Motley Fool
History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492
↗
November 04, 2026
This dividend ETF has delivered surprisingly strong growth for the past 15 years.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Stocks
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
↗
November 03, 2026
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via
The Motley Fool
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively
↗
November 03, 2026
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
Via
The Motley Fool
Topics
Economy
Tempus AI Surges on Earnings Beat, But Can the Rally Last?
↗
November 03, 2026
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
Initial Public Offering
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
November 03, 2026
From
Merck & Co., Inc.
Via
Business Wire
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs
↗
November 02, 2026
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Via
The Motley Fool
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
November 02, 2026
From
Merck & Co., Inc.
Via
Business Wire
Why Merck Stock Flew Higher on Friday
↗
October 30, 2026
Investors were still buying it in the afterglow of its latest quarterly earnings release.
Via
The Motley Fool
Topics
Intellectual Property
MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
October 30, 2026
Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil...
Via
StockStory
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
October 30, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
October 30, 2026
From
The Law Offices of Howard G. Smith
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.